7-溴-2-氯喹喔啉 | 89891-65-6

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 7-溴-2-氯喹喔啉
• 英文名称: 7-bromo-2-chloroquinoxaline
• 英文别名: 2-chloro-7-bromoquinoxaline
• CAS: 89891-65-6
• 化学式: C₈H₄BrClN₂
• mdl: MFCD02955309
• 分子量: 243.49
• InChiKey: AZUMKBQKUXTHCM-UHFFFAOYSA-N

物化性质

• 沸点：
  312.5±37.0 °C(Predicted)
• 密度：
  1.762

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Bromo-2-chloroquinoxaline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Bromo-2-chloroquinoxaline
CAS number: 89891-65-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H4BrClN2
Molecular weight: 243.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

7-溴-2-氯喹喔啉是一种杂环衍生物，可用作有机中间体。该化合物可通过以下步骤制备：首先以2-羟基喹喔啉为原料进行溴代反应，生成7-溴-2-氯喹喔啉；随后与三氯氧磷反应即可得到目标产物。

反应信息

• 作为反应物：
  描述：

  7-溴-2-氯喹喔啉 在 palladium diacetate 、 sodium carbonate 、 caesium carbonate 、 三苯基膦 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 水 、 甲苯 为溶剂， 反应 32.0h， 生成 厄达替尼
  参考文献：
  名称：

  erdafitinib 的新型聚合合成

  摘要：

  从市售化学品 quinoxalin-2-ol、4-bromo-1-methyl-1 H -pyrazole 和 2-bromo-1,1-开发了 20 g 规模的 erdafitinib 的新聚合合成路线二甲氧基乙烷。关键中间体 3,5-二甲氧基苯基-异丙基乙烷-1,2-二胺 ( 17 ) 由 2-溴-1,1-二甲氧基乙烷制备，两步收率为 89%，纯度为 98.8%。Erdafitinib 是从 7-bromo-2-(1-methyl- 1H -pyrazol -4-yl) quinoxaline ( 8 ) 和17中获得的，产率为 89%，纯度为 99.4%。该收敛合成路线共有7步，总收率为54%。

  DOI：

  10.1002/jhet.4544
• 作为产物：
  描述：

  7-溴-2(1H)-喹喔啉酮 在 三氯氧磷 作用下， 反应 2.0h， 以96%的产率得到7-溴-2-氯喹喔啉
  参考文献：
  名称：

  erdafitinib 的新型聚合合成

  摘要：

  从市售化学品 quinoxalin-2-ol、4-bromo-1-methyl-1 H -pyrazole 和 2-bromo-1,1-开发了 20 g 规模的 erdafitinib 的新聚合合成路线二甲氧基乙烷。关键中间体 3,5-二甲氧基苯基-异丙基乙烷-1,2-二胺 ( 17 ) 由 2-溴-1,1-二甲氧基乙烷制备，两步收率为 89%，纯度为 98.8%。Erdafitinib 是从 7-bromo-2-(1-methyl- 1H -pyrazol -4-yl) quinoxaline ( 8 ) 和17中获得的，产率为 89%，纯度为 99.4%。该收敛合成路线共有7步，总收率为54%。

  DOI：

  10.1002/jhet.4544
• 作为试剂：
  描述：

  6-bromo-3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-3H-imidazo[4,5-b]pyridin-2-amine 、 7-溴-2-氯喹喔啉 在 7-溴-2-氯喹喔啉 作用下， 以41的产率得到3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine
  参考文献：
  名称：

  PHARMACEUTICAL FORMULATIONS OF TROPOMYOSIN RELATED KINASE (TRK) INHIBITORS

  摘要：

  本发明揭示了含有肌动蛋白相关激酶抑制剂（“Trk抑制剂”）的制药配方。这些制药配方包括以其单水合物形式呈微晶悬浮制剂的3-（3-甲氧基-4-（（4-甲氧基苄基）氧基）苯基）-6-（1-甲基-1H-吡唑-4-基）-3H-咪唑并[4,5-b]吡啶-2-胺，该单水合物形式具有比无水合物形式更好的特性，并且还包括延长释放制剂。延长释放的制药配方包括3-（3-甲氧基-4-（（4-甲氧基苄基）氧基）苯基）-6-（1-甲基-1H-吡唑-4-基）-3H-咪唑并[4,5-b]吡啶-2-胺负载的微球。

  公开号：

  US20180000728A1

文献信息

• [EN] PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET DE TRIAZINE, ET LEUR UTILISATION COMME INHIBITEURS D'AXL
  申请人：PFIZER

  公开号：WO2016097918A1

  公开（公告）日：2016-06-23

  Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

  公式(I)的化合物： (I) 这些化合物的制备方法，包含这些化合物的组合物，以及这些化合物的用途。
• SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF
  申请人：Impact Therapeutics (Shanghai), Inc

  公开号：EP3567041A9

  公开（公告）日：2022-04-20

  The disclosure relates to substituted fused heteroaromatic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A1-A4, B1-B3, D1-D4 and R1-R3 are defined herein. Compounds having Formula I are kinalse inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.

  本公开涉及取代的融合杂芳香化合物及其用途。具体而言，本公开提供了以下式I的化合物： 或其药用可接受的盐或前药，其中A1-A4、B1-B3、D1-D4和R1-R3如本文所述定义。具有式I的化合物是激酶抑制剂。因此，本公开的化合物可用于治疗由DDR功能缺陷引起的临床状况，如癌症。
• [EN] COMBINATION OF KINASE INHIBITORS AND USES THEREOF<br/>[FR] COMBINAISON D'INHIBITEURS DE KINASE ET SES UTILISATIONS
  申请人：INTELLIKINE LLC

  公开号：WO2014151147A1

  公开（公告）日：2014-09-25

  The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

  本发明提供了一种治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的方法。另一方面，该发明提供了一种治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的方法。在另一个方面，提出了一种抑制细胞内Akt（S473）和Akt（T308）磷酸化的方法。本发明还提供了一种有效治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的药物套装。
• COMBINATION OF KINASE INHIBITORS AND USES THEREOF
  申请人：INTELLIKINE, LLC

  公开号：US20150030588A1

  公开（公告）日：2015-01-29

  The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.

  本发明提供了一种治疗与PI3-激酶a和/或受体酪氨酸激酶（RTK）有关的疾病状况的方法。另一方面，该发明提供了一种治疗与PI3-激酶α和/或受体酪氨酸激酶（RTK）有关的疾病状况的方法。另一方面，提出了一种抑制细胞中Akt（S473）磷酸化的方法。
• QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS
  申请人：CHAUDHARI Amita

  公开号：US20080293706A1

  公开（公告）日：2008-11-27

  Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.

  发明了一种使用喹喔啉衍生物抑制PI3激酶活性/功能的方法。还发明了一种通过给予喹喔啉衍生物来治疗自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官功能衰竭、肾脏疾病、血小板聚集、癌症、精子活动力、移植排斥、移植物排斥和肺部损伤等一种或多种疾病状态的方法。